References
- T. H. Grossman, Tetracycline antibiotics and resistance, Cold Spring Harbor Perspect. Med. 6(4) (2016) Article ID a025387 (24 pages); https://doi.org/10.1101/cshperspect.a025387
- K. L. LaPlante, A. Dhand, K. Wright and M. Lauterio, Re-establishing the utility of tetracycline-class antibiotics for current challenges with antibiotic resistance, Ann. Med. 54(1) (2022) 1686–1700; https://doi.org/10.1080/07853890.2022.2085881
- H. G. Colaco, A. Barros, A. Neves-Costa, E. Seixas, D. Pedroso, T. Velho, K. L. Willmann, P. Faisca, G. Grabmann, H. S. Yi, M. Shong, V. Benes, S. Weis, T. Kocher and L. F. Moita, Tetracycline antibiotics induce host-dependent disease tolerance to infection, Immunity 54(1) (2021) 53–67; https://doi.org/10.1016/j.immuni.2020.09.011
- G. G. Zhanel, J. Esquivel, S. Zelenitsky, C. K. Lawrence, H. J. Adam, A. Golden, R. Hink, L. Berry, F. Schweizer, M. A. Zhanel, D. Bay, P. R. S. Lagace-Wiens, A. J. Walkty, J. P. Lynch, 3rd and J. A. Karlowsky, Omadacycline: A novel oral and intravenous aminomethylcycline antibiotic agent, Drugs 80(3) (2020) 285–313; https://doi.org/10.1007/s40265-020-01257-4
- P. Y. Huang, C. K. Hsu, H. J. Tang and C. C. Lai, Eravacycline: A comprehensive review of in vitro activity, clinical efficacy, and real-world applications, Expert Rev. Anti Infect. Ther. 22(6) (2024) 387–398; https://doi.org/10.1080/14787210.2024.2351552
- S. Yaghoubi, A. O. Zekiy, M. Krutova, M. Gholami, E. Kouhsari, M. Sholeh, Z. Ghafouri and F. Maleki, Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: Narrative review, Eur. J. Clin. Microbiol. Infect. Dis. 41(7) (2021) 1003–1022; https://doi.org/10.1007/s10096-020-04121-1
- Tigecycline FDA Label, revised 4/2025; https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/dd58e0c3-d8a8-4cf2-96f8-9dd08f309579/spl-doc?hl=tigecycline; last access date July 31, 2025
- Omadacycline FDA Label, revised 3/2025; https://nctr-crs.fda.gov/fdalabel/services/spl/setids/51591524-4703-44c6-8bde-dce3e6a463d1/spl-doc?hl=omadacycline; last access date July 31, 2025.
- Eravacycline FDA Label, revised 3/2025; https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/a4b188d4-f467-470c-ad7b-25ffbdd8862a/spl-doc?hl=eravacycline; last access date July 31, 2025.
- Q. Kaewpoowat and L. Ostrosky-Zeichner, Tigecycline: A critical safety review, Expert Opin. Drug Saf. 14(2) (2015) 335–342; https://doi.org/10.1517/14740338.2015.997206
- F. Lin, R. He, B. Yu, B. Deng, B. Ling and M. Yuan, Omadacycline for treatment of acute bacterial infections: A meta-analysis of phase II/III trials, BMC Infect. Dis. 23(1) (2023) Article ID 232 (10 pages); https://doi.org/10.1186/s12879-023-08212-0
- R. Meng, X. Guan, L. Sun, Z. Fei, Y. Li, M. Luo, A. Ma and H. Li, The efficacy and safety of eravacycline compared with current clinically common antibiotics in the treatment of adults with complicated intra-abdominal infections: A Bayesian network meta-analysis, Front. Med. (Lausanne) 9 (2022) Article ID 935343 (15 pages); https://doi.org/10.3389/fmed.2022.935343
- K. Eljaaly, J. K. Ortwine, M. Shaikhomer, T. A. Almangour and M. Bassetti, Efficacy and safety of eravacycline: A meta-analysis, J. Glob. Antimicrob. Resist. 24 (2021) 424–428; https://doi.org/10.1016/j.jgar.2021.02.009
- S. H. Lan, S. P. Chang, C. C. Lai, L. C. Lu and C. M. Chao, The efficacy and safety of omadacycline in treatment of acute bacterial infection: A systemic review and meta-analysis of randomized controlled trials, Medicine (Baltimore) 98(51) (2019) e18426 (6 pages); https://doi.org/10.1097/MD.0000000000018426
- P. Inácio, A. Cavaco and M. Airaksinen, The value of patient reporting to the pharmacovigilance system: A systematic review, Br. J. Clin. Pharmacol. 83(2) (2017) 227–246; https://doi.org/10.1111/bcp.13098
- T. Sakaeda, A. Tamon, K. Kadoyama and Y. Okuno, Data mining of the public version of the FDA Adverse Event Reporting System, Int. J. Med. Sci. 10(7) (2013) 796–803; https://doi.org/10.7150/ijms.6048
- E. G. Brown, L. Wood and S. Wood, The medical dictionary for regulatory activities (MedDRA), Drug Saf. 20(2) (1999) 109–117; https://doi.org/10.2165/00002018-199920020-00002
- E. P. van Puijenbroek, A. Bate, H. G. Leufkens, M. Lindquist, R. Orre and A. C. Egberts, A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions, Pharmacoepidemiol. Drug Saf. 11(1) (2002) 3–10; https://doi.org/10.1002/pds.668
- C. Khouri, T. Nguyen, B. Revol, M. Lepelley, A. Pariente, M. Roustit and J. L. Cracowski, Leveraging the variability of pharmacovigilance disproportionality analyses to improve signal detection performances, Front. Pharmacol. 12(1) (2021) Article ID 668765 (7 pages); https://doi.org/10.3389/fphar.2021.668765
- K. J. Rothman, S. Lanes and S. T. Sacks, The reporting odds ratio and its advantages over the proportional reporting ratio, Pharmacoepidemiol. Drug Saf. 13(8) (2004) 519–523; https://doi.org/10.1002/pds.1001
- A. Kumar, The newly available FAERS public dashboard: Implications for health care professionals, Hosp. Pharm. 54(2) (2019) 75–77; https://doi.org/10.1177/0018578718795271
- L. Wang, D. Liu, Y. Lv, L. Cui, Y. Li, T. Li, H. Song, Y. Hao, J. Shen, Y. Wang and T. R. Walsh, Novel plasmid-mediated tet(X5) gene conferring resistance to tigecycline, eravacycline, and omadacycline in a clinical Acinetobacter baumannii isolate, Antimicrob. Agents Chemother. 64(1) (2019) Article ID 10.1128/AAC.01326-19 (5 pages); https://doi.org/10.1128/AAC.01326-19
- A. J. Kunz Coyne, S. Alosaimy, K. Lucas, A. M. Lagnf, T. Morrisette, K. C. Molina, A. DeKerlegand, M. R. Schrack, S. L. Kang-Birken, A. L. V. Hobbs, J. Agee, N. B. Perkins, M. Biagi, M. Pierce, J. Truong, J. Andrade, J. Bouchard, T. Gore, M. A. King, B. M. Pullinger, K. C. Claeys, S. Herbin, R. Cosimi, S. Tart, M. P. Veve, B. M. Jones, L. M. Rojas, A. K. Feehan, M. R. Scipione, J. J. Zhao, P. Witucki, M. J. Rybak and A. Babiker, Eravacycline, the first four years: health outcomes and tolerability data for 19 hospitals in 5 U.S. regions from 2018 to 2022, Microbiol. Spectr. 12(1) (2024) e0235123 (14 pages); https://doi.org/10.1128/spectrum.02351-23
- J. Rello, Pharmacokinetics, pharmacodynamics, safety and tolerability of tigecycline, J. Chemother. 17(Suppl. 1) (2005) 12–22; https://doi.org/10.1179/joc.2005.17.Supplement-1.12
- L. A. Bundrant, E. Tzanis, L. Garrity-Ryan, S. Bai, S. Chitra, A. Manley and S. Villano, Safety and pharmacokinetics of the aminomethylcycline antibiotic omadacycline administered to healthy subjects in oral multiple-dose regimens, Antimicrob. Agents Chemother. 62(2) (2018) Article ID 10.1128/AAC.01487-17 (9 pages); https://doi.org/10.1128/AAC.01487-17
- J. Ren, Y. Zheng, H. Du, S. Wang, L. Liu, W. Duan, Z. Zhang, L. Heng and Q. Yang, Antibiotic-- induced black hairy tongue: Two case reports and a review of the literature, J. Int. Med. Res. 48(10) (2020) Article ID 300060520961279 (11 pages); https://doi.org/10.1177/0300060520961279
- N. Shaheen and D. F. Ransohoff, Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: Scientific review, JAMA 287(15) (2002) 1972–1981; https://doi.org/10.1001/jama.287.15.1972
- J. S. Overcash, P. Bhiwandi, L. Garrity-Ryan, J. Steenbergen, S. Bai, S. Chitra, A. Manley and E. Tzanis, Pharmacokinetics, safety, and clinical outcomes of omadacycline in women with cystitis: Results from a phase 1b study, Antimicrob. Agents Chemother. 63(5) (2019) Article ID 10.1128/AAC.02083-18 (10 pages); https://doi.org/10.1128/AAC.02083-18
- H. Arafat, D. Sadaqa and A. Sabateen, Tigecycline-induced pancreatitis in a patient with recurrent malignancy: A case report and literature review, Ann. Med. Surg. (London) 86(6) (2024) 3717–3720; https://doi.org/10.1097/MS9.0000000000002077
- B. S. Maringanti, V. M. Ganipisetti, S. S. Jun and M. I. Flores, Tigecycline tango: a case of antibiotic-induced pancreatitis, Cureus 15(9) (2023) e44538 (3 pages); https://doi.org/10.7759/cureus.44538
- S. Opal, T. M. File, T. van der Poll, E. Tzanis, S. Chitra and P. C. McGovern, An integrated safety summary of omadacycline, a novel aminomethylcycline antibiotic, Clin. Infect. Dis. 69(Suppl. 1) (2019) S40–S47; https://doi.org/10.1093/cid/ciz398
- C. M. Mingora, W. Bullington, P. E. Faasuamalie, A. Levin, G. Porter, R. Stadnick, C. D. Varley, D. Addrizzo-Harris, C. L. Daley, K. N. Olivier, K. L. Winthrop, S. E. Dorman and P. A. Flume, Long-term safety and tolerability of omadacycline for the treatment of mycobacterium abscessus infections, Open Forum Infect. Dis. 10(7) (2023) Article ID ofad335 (6 pages); https://doi.org/10.1093/ofid/ofad335
- P. C. McGovern, M. Wible, J. M. Korth-Bradley and A. Quintana, Pancreatitis in tigecycline Phase 3 and 4 clinical studies, J. Antimicrob. Chemother. 69(3) (2014) 773–778; https://doi.org/10.1093/jac/dkt427
- N. Cui, H. Cai, Z. Li, Y. Lu, G. Wang and A. Lu, Tigecycline-induced coagulopathy: A literature review, Int. J. Clin. Pharm. 41(6) (2019) 1408–1413; https://doi.org/10.1007/s11096-019-00912-5
- H. Pieringer, B. Schmekal, G. Biesenbach and E. Pohanka, Severe coagulation disorder with hypofibrinogenemia associated with the use of tigecycline, Ann. Hematol. 89(10) (2010) 1063–1064; https://doi.org/10.1007/s00277-010-0911-7
- Q. Fan, W. Huang, Y. Weng, X. Xie and Z. Shi, Hypofibrinogenemia induced by high-dose tigecycline-case report and review of literature, Medicine (Baltimore) 99(43) (2020) e22638 (5 pages); https://doi.org/10.1097/MD.0000000000022638
- H. Duan, L. Yu, F. Tian, Q. Zhai, L. Fan and W. Chen, Antibiotic-induced gut dysbiosis and barrier disruption and the potential protective strategies, Crit. Rev. Food Sci. Nutr. 62(6) (2022) 1427–1452; https://doi.org/10.1080/10408398.2020.1843396
- B. E. Dawes, J. Gao, C. Atkins, J. T. Nelson, K. Johnson, P. Wu and A. N. Freiberg, Human neural stem cell-derived neuron/astrocyte co-cultures respond to La Crosse virus infection with proinflammatory cytokines and chemokines, J. Neuroinflammation 15(1) (2018) Article ID 315 (15 pages); https://doi.org/10.1186/s12974-018-1356-5
- S. Andrei, G. Droc and G. Stefan, FDA approved antibacterial drugs: 2018–2019, Discoveries (Craiova) 7(4) (2019) e102 (11 pages); https://doi.org/10.15190/d.2019.15
- L. Vidal, I. Ben Dor, M. Paul, N. Eliakim-Raz, E. Pokroy, K. Soares-Weiser and L. Leibovici, Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients, Cochrane Database Syst. Rev. (10) (2013) Article ID CD003992 (66 pages); https://doi.org/10.1002/14651858.CD003992.pub3
- H. K. Li, M. Scarborough, R. Zambellas, C. Cooper, I. Rombach, A. S. Walker, B. A. Lipsky, A. Briggs, A. Seaton, B. Atkins, A. Woodhouse, A. Berendt, I. Byren, B. Angus, H. Pandit, D. Stubbs, M. McNally, G. Thwaites and P. Bejon, Oral versus intravenous antibiotic treatment for bone and joint infections (OVIVA): Study protocol for a randomised controlled trial, Trials 16 (2015) Article ID 583 (12 pages); https://doi.org/10.1186/s13063-015-1098-y
- S. Villano, J. Steenbergen and E. Loh, Omadacycline: development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections, Future Microbiol. 11(1) (2016) 1421–1434; https://doi.org/10.2217/fmb-2016-0100
- S. Lucas, J. Ailani, T. R. Smith, A. Abdrabboh, F. Xue and M. S. Navetta, Pharmacovigilance: Reporting requirements throughout a product’s lifecycle, Ther. Adv. Drug Saf. 13(1) (2022) Article ID 20420986221125006 (16 pages); https://doi.org/10.1177/20420986221125006
- K. Staller, H. P. Parkman, K. B. Greer, D. A. Leiman, M. J. Zhou, S. Singh, M. Camilleri, O. Altayar (on behalf of the AGA Clinical Guidelines Committee), AGA clinical practice guideline on management of gastroparesis, Gastroenterology 169(5) (2025) 828–861; https://doi.org/10.1053/j.gastro.2025.08.004